Boston, MA 10/07/2014 (wallstreetpr) – VIVUS, Inc. (NASDAQ:VVUS) is claiming that its Qsymia has the potential to treat obese or overweight patients with type 2 diabetes. The company made the disclosure through its paper that was published online in the Diabetes Care journal.
Studies Undertaken
The paper elaborated the clinical results in which, Qsymia was found out to be a helpful in weight management. The therapy, when combined with a reduced calorie diet and increased physical activity helped subjects within the initial body mass index (BMI) range of 30 kg/m2 to 27/kg m2 and higher. These subjects necessarily had one weight related medical condition present; that is high blood pressure, high cholesterol or type 2 diabetes.
The author of the paper based their views on results of two randomized placebo-controlled clinical studies spread across 56 weeks. The studies were divided into phase 2 study and phase 3 study. Under these studies, both overweight and obese patients having type 2 diabetes were treated through PHEN/TPM ER and lifestyle modification. Further, under phase 3, patients were treated with either metformin or diet alone during the entry into the study. While patients under phase 2 had to be dealt with more intensive therapy due to the long duration of diabetes in them.
Results
At the end of 56 weeks, the results of the studies showed that the weight loss in subjects under PHEN/TPM/ER was significant by -9.4% then -2.7% attained under placebo. Moreover, the treated patients found less need to follow diabetes medications than those in the placebo group. However, some of the common associated adverse events in the therapy were constipation, paraesthesia and insomnia. Thus, the data is a full proof to establish the fact that weight loss is possible in type 2 diabetes patients when combined with medical therapy. Moreover, the treatment also has a significant impact on cardiometabolic leading to lowering of HbA1c levels.
